HIGHLIGHTS
- who: Jianyang Liu from the National Institutes for Food and Drug Control, China, NHC Key Laboratory of Research on Quality and Huazhong University of Science and have published the paper: Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines, in the Journal: (JOURNAL) of January/15,/2022
- what: The safety of this approach has also not been adequately demonstrated yet . Surrogate endpoints should be explored, and the investigation of correlations between vaccine preventive vaccines immunogenicity and effectiveness, and reasonable immunological surrogate endpoints are encouraged (trial) during clinical R and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.